This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by McMaster University.
Recruitment status was:  Not yet recruiting
Information provided by:
McMaster University Identifier:
First received: March 17, 2009
Last updated: NA
Last verified: March 2009
History: No changes posted
The primary objectives of this exploratory study are to evaluate the effects of bosentan on hemodynamics (via cardiac catheterization) during exercise in patients with Pulmonary Arterial Hypertension (PAH) who have abnormal hemodynamics during exercise but normal hemodynamics at rest. The authors hypothesize that early treatment may change the course of disease progression by improving hemodynamics during exercise, thus delaying disease progression.

Condition Intervention Phase
Hypertension, Pulmonary Connective Tissue Disease Drug: bosentan Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Evaluate the Effect of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

Resource links provided by NLM:

Further study details as provided by McMaster University:

Primary Outcome Measures:
  • The primary outcome is the change in the following hemodynamics during exercise: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output∕cardiac input (CO∕CI), mean right arterial pressure (mRAP) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Change in hemodynamics at rest: pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (mPAP), cardiac output/cardiac input (CO∕CI), mean right arterial pressure (mRAP) [ Time Frame: 6 months ]

Estimated Enrollment: 10
Study Start Date: April 2009
Estimated Study Completion Date: April 2010
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bosentan Drug: bosentan
bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women ≥ 18 years of age
  • For female patients, only non-pregnant women who are surgically sterile, postmenopausal or have documented infertility (over 50 years of age and amenorrheic for at least 1 year), or those of childbearing potential using one of the following methods of contraception:

    • Barrier-type devices (e.g., condom, diaphragm) used ONLY in combination with a spermicide. A double-barrier method is recommended.
    • Intrauterine devices (IUDs)
    • Oral contraceptives, if used in combination with a barrier method
  • Body weight of 40 kg or higher
  • Patients diagnosed with connective tissue disease
  • Hemodynamics at rest, based on cardiac catheterization, should be as follows:

    • Mean pulmonary arterial pressure (mPAP) : 18 - 25 mmHg
    • PCWP ≤ 15 mmHg
  • Hemodynamics during exercise, based on cardiac catheterization, should be as follows: mPAP > 30 mmHg
  • Provide written informed consent

Exclusion Criteria:

  • PAH associated with any other condition
  • Severe obstructive lung disease : FEV1∕ FVC <0.5
  • Total lung capacity <60% of normal predicted value
  • Unable or unwilling have a cardiac catheterization procedure
  • Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements (6-MWT)
  • Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements
  • Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C
  • AST and ∕or ALT > 3 times uln
  • Hemoglobin concentration > 25% below the lower limit of normal
  • Systolic blood pressure < 85 mm Hg
  • Pregnancy or breast-feeding
  • Treatment or planned treatment with another investigational drug
  • Treatment with an endothelin receptor antagonist, phosphodiesterase type 5 inhibitor, or with prostanoids (excluding acute administration during a catheterization procedure to test vascular reactivity) within 2 months of inclusion
  • Treatment with calcineurin-inhibitors (i.e., cyclosporine A and tacrolimus), fluconazole, glibenclamide (glyburide) within 1 week of study start;
  • Known hypersensitivity to bosentan or any of the excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00864201

Contact: Christine Bradley, MD 905-546-9993

Canada, Ontario
Victoria Medical Center Not yet recruiting
Hamilton, Ontario, Canada, L8L 5G4
Principal Investigator: Christine Bradley, MD         
Sponsors and Collaborators
Hamilton Health Sciences Corporation
Principal Investigator: Christine Bradley Hamilton Health Sciences Corporation
  More Information

Responsible Party: Dr. Christine Bradley, Victoria Medical Centre Identifier: NCT00864201     History of Changes
Other Study ID Numbers: PAH-CTD-2007
Study First Received: March 17, 2009
Last Updated: March 17, 2009

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Hypertension, Pulmonary
Connective Tissue Diseases
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Antihypertensive Agents
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on August 21, 2017